Philips announced the main terms of an agreement it reached in January with the U.S. government on its new sleep apnea machines, which has already cost the company over 360.
A mandibular advancement device was non-inferior to standard of care CPAP to reduce blood pressure in patients with hypertension and sleep apnea in the CRESCENT trial.